Spark Signs an Exclusive Global Licensing Agreement with CombiGene for CG01 to Treat Focal Epilepsy

Shots:

• Spark to get exclusive, WW license to develop, manufacture and commercialize CG01 whereas CombiGene will continue to execute aspects of the preclinical program
• The companies will work together and will leverage their knowledge to address unmet needs for people living with drug-resistant focal epilepsy
• CG01 is an investigational gene therapy that aims to treat drug resistant focal epilepsy

Click here to­ read full press release/ article | Ref: Spark Therapeutics | Image: Ophthamology Innovation Summit